Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Cipla
Farmers Insurance
Citi
Healthtrust
Accenture
AstraZeneca
Argus Health
Daiichi Sankyo

Generated: May 24, 2018

DrugPatentWatch Database Preview

Claims for Patent: 5,554,639

« Back to Dashboard

Summary for Patent: 5,554,639
Title: Medicaments
Abstract:3-[2-(dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulphonamide sulphate salt (2:1) and pharmaceutically acceptable solvates thereof are disclosed. The compound is of use in the preparation of pharmaceutical compositions, particularly for intranasal formulations, for use in the treatment of conditions associated with cephalic pain, in particular migraine.
Inventor(s): Craig; Joanne (Ware, GB3), Crookes; Derek L. (Ware, GB3), Skittrall; Stephen J. (Ware, GB3)
Assignee: Glaxo Group Limited (London, GB2)
Application Number:08/460,791
Patent Claims: 1. An intranasal pharmaceutical composition for intranasal administration which comprises an aqueous solution containing an intranasally effective amount of 3-[2-(dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulphonamide sulphate salt (2:1) or a physiologically acceptable solvate thereof as active ingredient together with a pharmaceutically acceptable carrier, wherein the aqueous solution has a pH range of 5 to 7.

2. A pharmaceutical composition as claimed in claim 1 which contains the salt in a concentration of 20 mgml.sup.-1 to 500 mgml.sup.-1.

3. A pharmaceutical composition as claimed in claim 1 which is formulated in unit dosage form comprising 0.5 to 100 mg of active ingredient.

4. An intranasal pharmaceutical composition which comprises a sterile aqueous solution of 3-[2-(dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulphonamide sulphate salt (2:1) or a physiologically acceptable solvate thereof in a concentration of 20 mgml.sup.-1 to 500 mgml.sup.-1, which solution has a pH in the range of pH 5 to pH 7.

5. A method of treating a human suffering from or susceptible to migraine, which comprises intranasally administering the composition of claim 1.

6. A method of treating a human suffering from or susceptible to migraine, which comprises intranasally administering the composition of claim 2.

7. A method of treating a human suffering from or susceptible to migraine, which comprises intranasally administering the composition of claim 3.

8. A method of treating a human suffering from or susceptible to migraine, which comprises intranasally administering the composition of claim 4.

9. A pharmaceutical composition as claimed in claim 4, wherein the solution has a pH in the range of 5.4 to 5.6.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
US Department of Justice
Merck
Chinese Patent Office
Queensland Health
Harvard Business School
Chubb
Accenture
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.